Recent events
Recent events tied to this brand in public sources.
Back to profile8 entries
2022
Biocon Biologics announces acquisition of Viatris biosimilars business
Biocon Biologics announced a definitive agreement to acquire Viatris' biosimilars business and related assets. The transaction was expected to close in the second half of 2022, subject to closing conditions, including certain regulatory approvals.
2022
Biocon announces Biocon Biologics–Covidshield Technologies merger
Biocon announced that its material subsidiary Biocon Biologics Ltd would merge with Serum Institute of India's wholly owned subsidiary Covidshield Technologies Pvt Ltd, subject to requisite approvals. Biocon Biologics will issue and allot 15% equity shares to Serum on a fully diluted basis.
2021
Biocon Biologics and Serum Institute Life Sciences announce strategic alliance
Biocon Biologics and Serum Institute Life Sciences announced a strategic alliance covering vaccine access, manufacturing and distribution, and development of antibodies targeting infectious diseases.
2020
Biocon Biologics launches Semglee in the US
Biocon Biologics launched Semglee, a drug to control high blood sugar, in the US.
2020
Biocon Biologics and Voluntis sign licensing agreement
Biocon Biologics' subsidiary Biocon Sdn. Bhd. and Voluntis signed a licensing agreement concerning Insulia, a digital therapeutic product for Type 2 diabetes patients.
2020
Biocon Biologics appoints MB Chinappa as CFO
Biocon Biologics appointed MB Chinappa as its chief financial officer. The article says the appointment was reported on December 7 but does not specify the year.
2019
Biocon Biologics acquires Pfizer Healthcare India research facility assets
Biocon said its subsidiary Biocon Biologics acquired R&D capital assets for a 60,000-square-foot research facility at Ticel Bio Park in Chennai from Pfizer Healthcare India. The financial terms were not disclosed.
2019
Biocon Biologics acquires Pfizer Healthcare research facility assets
Biocon Biologics acquired the R&D capital assets of a 60,000-square-foot research facility at Ticel Bio Park in Chennai from Pfizer Healthcare. The amount was undisclosed.